Hitting the Right Spot: Advances in the Treatment of NSCLC with Uncommon EGFR Mutations

While the majority of patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) carry “common” EGFR mutations that are easily targeted with standard TKIs, up to 20% of these patients have uncommon mutations that are more difficult to treat. Uncommon EGFR mutations, including the G719X, S768I, and L861Q point mutations and exon 20 insertions, are more difficult to treat, have fewer treatment options, and are associated with a poorer prognosis. In recent years, novel treatments with efficacy against uncommon EGFR mutations have emerged. The EGFR TKI afatinib has been specifically approved for the treatment of G719X, S768I, and L861Q point mutations, and two novel EGFR targeted therapies—amivantamab and mobocertinib—have recently been granted Breakthrough Therapy Designation by the FDA for the efficacy against exon 20 insertions.

This activity, Hitting the Right Spot: Advances in the Treatment of NSCLC with Uncommon EGFR Mutations, will provide oncology clinicians with information on the biology and challenges associated with uncommon EGFR mutations, the latest guidance on identifying patients with these mutations, and safety and efficacy data for novel treatment options for patients who carry these mutations.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

In collaboration with

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Oncology.